Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the combination of finasteride and doxazosina was more effective in reducing the long-term progression of benign prostatic hyperplasia compared to monotherapy.

Finasteride and dutasteride can affect sexual function in BPH patients.

Tamsulosin works faster, but both drugs have similar effects after 6 months.

This study discusses the difficulties in interpreting and communicating the association of 5α-reductase inhibitors with impaired libido and erectile dysfunction in men with benign prostatic hyperplasia due to the use of odds ratios instead of relative risks.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Patients follow treatment well, but many change medicines; good information helps compliance.

This study found that finasteride test and reference tablets are bioequivalent in healthy male volunteers, with no significant differences in their pharmacokinetic parameters.

Finasteride helps treat male hair loss but may lower sex drive.

The FDA approved using Cialis with Proscar for better treatment options.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This study concluded that male patients with improved lower urinary tract symptoms may have a lower risk of death, suggesting a potential benefit of treating symptoms beyond just managing patient discomfort.

This study investigated the effects of 5-alpha-reductase inhibitors on penile histomorphometry in both normotensive and hypertensive rats, reporting no significant changes between treated and untreated groups.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review reports that while intracavernosal platelet-rich plasma is considered safe for treating erectile dysfunction, its efficacy remains unclear due to variable clinical trial protocols.

In this study, the researchers developed and optimized a bilayer tablet containing Tamsulosin and Finasteride, achieving sustained and immediate drug release with favorable release kinetics, including first-order and anomalous diffusion mechanisms, through in vitro testing.

This study confirmed that an injectable implant known as RISUG-PH™, when administered via the vas deferens, successfully delivers the drug Finasteride to the prostate in male rats for up to 28 days, suggesting a potential localized alternative to oral delivery methods.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.

This study found that the orally disintegrating tablet and standard tablet formulations of finasteride met bioequivalence criteria in fasting healthy adult male Han Chinese volunteers, although there was a significant difference in time to maximum concentration.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.